![](/images/graphics-bg.png)
RASBRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
المؤلفون المشاركون
An, Guangyu
Yao, Jiannan
Ge, Yang
Zang, Wanchun
Weygant, Nathaniel
Yu, Pan
Li, Lei
Rao, Guanhua
Jiang, Zhi
Yan, Rui
He, Linjia
Yu, Yang
Jin, Mulan
Cheng, Gang
المصدر
Canadian Journal of Gastroenterology and Hepatology
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-03-07
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Background.
Since circulating tumor DNA (ctDNA) offers clear advantages as a minimally invasive method for tumor monitoring compared with tumor tissue, we aimed to evaluate genotyping ctDNA using a next-generation sequencing- (NGS-) based panel to identify the prognostic value of mutation status in metastatic colorectal cancer (mCRC) patients with primary tumor resected and with subsequent lines of treatment in this study.
Methods.
76 mCRC patients treated in Beijing Chao-Yang Hospital from 2011 to 2017 were enrolled.
Genotyping of RAS/BRAF in tumor tissue and ctDNA was determined by ARMS PCR and with a 40-gene panel using NGS, respectively.
Patient clinicopathologic features and RAS/BRAF gene mutation status were evaluated by survival analysis for disease-free survival (DFS) and progression-free survival (PFS).
Results.
Among 76 patients, KRAS distributions were not significantly correlated with any clinicopathologic features.
The concordance between tumor tissue and ctDNA KRAS mutation was 81.25%.
Mutations of RAS/BRAF had no significant impact on DFS after surgery (hazard ratio (HR), 1.205; 95% CI, 0.618 to 2.349; P = 0.5837 ) but prognosticated poorer PFS in subsequent first-line therapy (HR, 3.351; 95% CI, 1.172 to 9.576; P = 0.024 ).
Conclusion.
ctDNA was comparable with tumor tissue for mutation detection.
RAS/BRAF mutations detected in ctDNA predict a worse PFS in mCRC patients with first-line chemotherapy.
Our results provide support for the prognostic value of RAS/BRAF ctDNA mutation detection in mCRC patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Yao, Jiannan& Zang, Wanchun& Ge, Yang& Weygant, Nathaniel& Yu, Pan& Li, Lei…[et al.]. 2018. RASBRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Canadian Journal of Gastroenterology and Hepatology،Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1130911
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Yao, Jiannan…[et al.]. RASBRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Canadian Journal of Gastroenterology and Hepatology No. 2018 (2018), pp.1-10.
https://search.emarefa.net/detail/BIM-1130911
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Yao, Jiannan& Zang, Wanchun& Ge, Yang& Weygant, Nathaniel& Yu, Pan& Li, Lei…[et al.]. RASBRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Canadian Journal of Gastroenterology and Hepatology. 2018. Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1130911
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1130911
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)